Tacere

Benitec Biopharma hit two key milestones recently in its effort to advance its expressed RNAi-based hepatitis C treatment TT-034 into the clinic, securing a commitment to sell A$7 million ($6.7 million) of its stock to new and existing shareholders and receiving a favorable revie

Shares of Benitec Biopharma resumed trading on the Australian Stock Exchange this week after the company announced that it had closed a A$800,000 ($821,760) private placement that it said would give it resources enough to fund a clinical trial of its recently reacquired hepatitis

With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.

Just six years after a troubled Benitec Biopharma licensed its expressed RNAi hepatitis C drug program to Tacere Therapeutics, a startup founded by former Benitec executives, the two companies have agreed to merge.

Rosetta Genomics announced that it has named Robert Wassman as its new chief medical officer and Dganit Bar as its new chief scientific officer.

Tacere Therapeutics is prepared to file an investigational new drug application for an expressed RNAi treatment for hepatitis C, but is looking to partner the program before doing so after previous collaborator Pfizer pulled back on its in-house RNAi drug efforts, according to Be

For instance, Tacere Therapeutics received $488,958 in two grants, the first of which supports development of a new hepatitis C treatment, as well as a previously undisclosed eye-disease program.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.